Erratum to: Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes (t2d): the carmelina randomised controlled trial

Christoph Wanner, Mark E. Cooper, Odd Erik Johansen, Robert Toto, Julio Rosenstock, Darren K. McGuire, Steven E. Kahn, Egon Pfarr, Sven Schnaidt, Maximilian von Eynatten, Jyothis T. George, Nicholas D. Gollop, Nikolaus Marx, John H. Alexander, Bernard Zinman, Vlado Perkovic, CARMELINA Invest

Research output: Contribution to journalArticlepeer-review


This is a correction to: Clinical Kidney Journal, Volume 14, Issue 1, January 2021, Pages 226–236,

In the originally published version of this manuscript, the legend for Figure 4 incorrectly directed the reader to the right side of the curve, this has been corrected to read: ‘Point estimates on the left side of the curve indicate a positive effect for LINA.’
Original languageEnglish
Pages (from-to)2136
Number of pages1
JournalClinical Kidney Journal
Issue number9
Early online date14 Jul 2021
Publication statusPublished - Sep 2021

Cite this